ArticleCancer discovery2022

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Alexander Muik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.